• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.

作者信息

Million Matthieu, Roussel Yanis, Gautret Philippe, Raoult Didier

机构信息

IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France.

IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, VITROME, Marseille, France.

出版信息

Int J Antimicrob Agents. 2021 Jan;57(1):106240. doi: 10.1016/j.ijantimicag.2020.106240.

DOI:10.1016/j.ijantimicag.2020.106240
PMID:33408019
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7779266/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb17/7779266/b0a89c3dcea8/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb17/7779266/b0a89c3dcea8/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb17/7779266/b0a89c3dcea8/gr1_lrg.jpg

相似文献

1
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.羟氯喹和阿奇霉素对新型冠状病毒肺炎患者严重急性呼吸综合征冠状病毒2清除率的影响：一项荟萃分析
Int J Antimicrob Agents. 2021 Jan;57(1):106240. doi: 10.1016/j.ijantimicag.2020.106240.
2
Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.用于2019冠状病毒病诊断的严重急性呼吸综合征冠状病毒2聚合酶链反应结果解读
Int J Antimicrob Agents. 2021 Jan;57(1):106238. doi: 10.1016/j.ijantimicag.2020.106238.
3
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.羟氯喹和阿奇霉素治疗COVID-19的效果：一项开放标签非随机临床试验的结果，意向性分析及临床结局的更新
Int J Antimicrob Agents. 2021 Jan;57(1):106239. doi: 10.1016/j.ijantimicag.2020.106239.
4
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.羟氯喹啉和阿奇霉素治疗新型冠状病毒肺炎的临床疗效及安全性概况
Int J Antimicrob Agents. 2021 Jan;57(1):106242. doi: 10.1016/j.ijantimicag.2020.106242.
5
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.羟氯喹和阿奇霉素用于治疗新型冠状病毒肺炎：重新审视一项开放标签非随机临床试验的结果
Int J Antimicrob Agents. 2021 Jan;57(1):106243. doi: 10.1016/j.ijantimicag.2020.106243.
6
Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.羟氯喹和阿奇霉素对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒载量的影响尚不确定。
Int J Antimicrob Agents. 2021 Jan;57(1):106169. doi: 10.1016/j.ijantimicag.2020.106169.
7
Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.羟氯喹治疗新型冠状病毒肺炎的疗效评估：一项开放标签非随机临床试验的二次分析
Int J Antimicrob Agents. 2021 Jan;57(1):106172. doi: 10.1016/j.ijantimicag.2020.106172.
8
Advanced statistical methods and designs for clinical trials for COVID-19.用于新型冠状病毒肺炎临床试验的先进统计方法与设计
Int J Antimicrob Agents. 2021 Jan;57(1):106167. doi: 10.1016/j.ijantimicag.2020.106167.
9
Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.羟氯喹啉与阿奇霉素联合治疗COVID-19患者的安全性概况。
Int J Antimicrob Agents. 2021 Jan;57(1):106236. doi: 10.1016/j.ijantimicag.2020.106236.
10
Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.近期文献不支持将羟氯喹与阿奇霉素联合用于新冠肺炎患者。
Int J Antimicrob Agents. 2021 Jan;57(1):106174. doi: 10.1016/j.ijantimicag.2020.106174.

引用本文的文献

1
The Clinical Course and Outcomes of Patients Hospitalized Due to COVID-19 during Three Pandemic Waves in Poland: A Single Center Observational Study.波兰三波疫情期间因新冠病毒病住院患者的临床病程及结局：一项单中心观察性研究
J Clin Med. 2022 Dec 13;11(24):7386. doi: 10.3390/jcm11247386.
2
Evaluation of clinical and laboratory characteristics and factors affecting mortality in 500 hospitalized COVID-19 patients: A retrospective study.500 例住院 COVID-19 患者的临床和实验室特征评估及其对死亡率的影响因素：一项回顾性研究。
Saudi Med J. 2022 Nov;43(11):1254-1259. doi: 10.15537/smj.2022.43.11.20220641.
3
Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy.

本文引用的文献

1
Can we use hydroxychloroquine to treat COVID-19 now?我们现在可以使用羟氯喹治疗新冠病毒疾病吗？
Int J Antimicrob Agents. 2021 Jan;57(1):106173. doi: 10.1016/j.ijantimicag.2020.106173.
2
Interferon-α2b Treatment for COVID-19.干扰素-α2b 治疗 COVID-19。
Front Immunol. 2020 May 15;11:1061. doi: 10.3389/fimmu.2020.01061. eCollection 2020.
3
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].羟氯喹治疗中度新型冠状病毒肺炎患者的一项试点研究
新冠病毒病的早期门诊治疗：意大利392例病例的回顾性分析
J Clin Med. 2022 Oct 18;11(20):6138. doi: 10.3390/jcm11206138.
4
Consumption Trends of Antibiotics in Brazil During the COVID-19 Pandemic.新冠疫情期间巴西抗生素的消费趋势
Front Pharmacol. 2022 Mar 21;13:844818. doi: 10.3389/fphar.2022.844818. eCollection 2022.
5
A Peek into Pandora's Box: COVID-19 and Neurodegeneration.窥探潘多拉魔盒：新冠病毒与神经退行性变
Brain Sci. 2022 Jan 30;12(2):190. doi: 10.3390/brainsci12020190.
6
Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway.关于新冠病毒病常用研究药物在胆固醇合成途径中的作用的考量。
Expert Opin Pharmacother. 2021 Jun;22(8):947-952. doi: 10.1080/14656566.2021.1897104. Epub 2021 Mar 11.
7
Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann.羟氯喹和阿奇霉素对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒清除的影响：对埃尔韦·塞利格曼的回应
Int J Antimicrob Agents. 2021 Mar;57(3):106306. doi: 10.1016/j.ijantimicag.2021.106306. Epub 2021 Feb 14.
8
Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.用于2019冠状病毒病诊断的严重急性呼吸综合征冠状病毒2聚合酶链反应结果解读
Int J Antimicrob Agents. 2021 Jan;57(1):106238. doi: 10.1016/j.ijantimicag.2020.106238.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. doi: 10.3785/j.issn.1008-9292.2020.03.03.
4
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
5
Randomized, controlled trials, observational studies, and the hierarchy of research designs.随机对照试验、观察性研究以及研究设计的层次结构。
N Engl J Med. 2000 Jun 22;342(25):1887-92. doi: 10.1056/NEJM200006223422507.